COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study
Scientific title
Do Beta-Blockers Affect the Use of Beta-Agonist Inhalers in COPD?
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Study type
Description of intervention(s) / exposure
Treatment: Drugs - bronchodilator response

Placebo Comparator: R302 - Daily placebo capsules

Active Comparator: R303 - Daily metoprolol 95mg capsules

Active Comparator: R304 - Daily propranolol 80mg capsules

Active Comparator: Open Label - Daily Metoprolol 190mg capsules

Treatment: Drugs: bronchodilator response

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Bronchodilator response to salbutamol after beta-blockers
Timepoint [1] 0 0
7-10 days
Primary outcome [2] 0 0
Incremental Shuttle Walk Test Result after taking beta-blockers
Timepoint [2] 0 0
7-10 days

Key inclusion criteria
- Clinical diagnosis of COPD

- > 40 years of age

- > 15 pack year smoking history
Minimum age
40 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Contra-indication to beta-blocker use

- Severe COPD FEV1 < 30% or 1 L

- Not responsive the methacholine

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people analysing the results/data
Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0

Funding & Sponsors
Primary sponsor type
Waikato Hospital
Other collaborator category [1] 0 0
Name [1] 0 0
Waikato Hospital Research Fund
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Brief summary
Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These
are very common conditions and many patients have both diseases. Beta-blocker drugs are
extensively used in the treatment of angina, high blood pressure and after heart attacks to
decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness
and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in
COPD patients as they may make the breathlessness worse, but it has now been established that
they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the
body and the investigators do not know if they can work together or if they would cancel each
other out. The investigators also do not know which of the different types of beta-blockers
now available are better for COPD patients. This study will investigate what happens to the
airways of people taking both of these drugs.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Bob Hancox, MD FRACP
Address 0 0
Waikato Hospital Research Unit
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications